Indian Chest Society Unveils Special Booklet On Cough Management

Hyderabad/ Delhi:  The Indian Chest Society (ICS) today unveiled a special booklet titled ‘Guidelines For Cough Management in India’, focusing on the comprehensive management of cough in India. This initiative comes at a crucial time when respiratory health is of paramount concern globally. The special booklet is part of ICS’ medical initiative supported by Dr. Reddy’s Laboratories Limited (Dr. Reddy’s), a global pharmaceutical company headquartered in Hyderabad, India as a scientific partner.

Through this booklet, ICS aims to illuminate the prevalence of cough, explore its diverse causes, and provide insights into its diagnosis and management. With dedicated sections on both dry and wet cough management, considerations regarding red flags, appropriate times for specialist referral, the relevance of fixed-dose combinations (FDCs), and a critical examination of banned FDCs in India, the booklet offers evidence-based strategies for clinicians to tailor their treatment approaches accordingly.

To enhance informed decision-making in clinical practice, the booklet also includes a section on fixed-dose combinations which are better alternatives to codeine-based combinations for managing dry cough, and sheds light on appropriate Beta-2 receptor agonists for wet cough management.

The distinguished panel of eight pulmonologists, comprising Dr. R Vijai Kumar, Vice President of ICS, Dr. Deepak Talwar, Honorary Secretary of ICS, Dr. Pradyut Waghray, Dr. Maulik Sanghvi, Dr. S Z Jafrey, Dr. Mahavir Modi, Dr. Meghana Subhash, and Dr. Visweswaran, has been instrumental in shaping the content of this booklet.

Speaking about the initiative, Dr. R Vijai Kumar from ICS said, “We believe that this initiative will serve as a valuable resource for healthcare professionals across the country, contributing to enhanced patient care and improved outcomes in cough management. We would also like to thank Dr. Reddy’s for providing scientific support.”

The booklet will be available on ICS’ website soon.


About The Indian Chest Society

The Indian Chest Society (ICS) is a not for profit registered society with the Society of Registrars (Registration No. 192-1980, dated 18th July 1980), for Respiratory & Pulmonary and other Physicians with interest in the specialty of Respiratory Medicine. A committee of eminent Chest Physicians, who were also the founding members took up the task to prepare the constitution of the society. The first General Body Meeting was held on 11th September 1981 at Hotel President, Mumbai, and the Constitution was adopted. For more info, please visit- https://www.myicsorg.net/

Related Posts

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

PharmEasy, the online medical platform emphasizes the importance of early prevention and regular health screenings to reduce the risk of diabetes. By encouraging individuals to undergo timely blood sugar tests,…

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

India’s pharmaceutical exporters have been offered a fresh business opportunity to expand their presence in Saudi Arabia, with Riyadh-based Al Hobail Medical Company seeking Indian manufacturing partners for the registration…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

UP expands food, drug testing capacity across all 18 divisions

UP expands food, drug testing capacity across all 18 divisions

Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

Medicines worth ₹14 lakh seized from unlicensed residential premises in Delhi

Medicines worth ₹14 lakh seized from unlicensed residential premises in Delhi